Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
Statistics in Medicine · 2026
DOI: 10.1002/sim.70424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2026. Verfasst von Hyejung Jung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Randomized Controlled Trials as Topic. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centre for Addiction and Mental Health.
Abstract (Originalsprache)
Phase 2 clinical trials typically rely on a single primary endpoint, yet in many settings, treatment efficacy must be demonstrated across multiple co‐primary endpoints. Such settings require intersection‐union hypothesis testing, in which the global null hypothesis is rejected only when all individual component hypotheses are rejected. Existing phase 2 designs for binary endpoints are largely restricted to single‐arm or single‐endpoint settings, or rely on large‐sample normal approximations for two‐arm trials, which may be inadequate when sample sizes are small. We developed exact and simulation‐based methods for designing two‐arm, two‐stage phase 2 trials with two co‐primary binary endpoints using the bivariate binomial distribution, allowing different correlations between endpoints across treatment arms. The proposed framework identifies optimal designs that minimize the expected sample size and minimax designs that minimize the maximum sample size, while allowing early termination for futility at the first stage. For small sample sizes (approximately per arm), the exact method is computationally feasible and yields analytically exact operating characteristics under the assumed bivariate binomial distribution. For larger sample sizes, however, exact computations become intensive. To address this, we evaluated a simulation‐based approach and a normal approximation by comparing their performance against the exact method. The simulation approach selected designs that closely matched those from the exact method, whereas the normal approximation often deviated. Therefore, we recommend the simulation‐based method as a computationally efficient and accurate alternative for moderate‐to‐large sample size trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
- Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.
- Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Hyejung Jung, Aya A Mitani, Clement Ma
Förderung
- Centre for Addiction and Mental Health
Zitieren
APA
Jung, H., Mitani, A. A., Ishrat Husain, M., & Ma, C. (2026). Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints. Statistics in Medicine. https://doi.org/10.1002/sim.70424
Vancouver
Jung H, Mitani AA, Ishrat Husain M, Ma C. Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints. Statistics in Medicine. 2026. doi:10.1002/sim.70424
BibTeX
@article{Jung2026,
author = {Jung, Hyejung and Mitani, Aya A and Ishrat Husain, M and Ma, Clement},
title = {Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints},
journal = {Statistics in Medicine},
year = {2026},
doi = {10.1002/sim.70424}
}
EUVIMED